HECA yields 1.93% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, HECA + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HECA + PFE for your $10,000?
HECA is a multi-asset strategy designed to maximize returns over rolling 12-month periods while limiting drawdowns to no more than 15%. Investments include asset classes such as equities, fixed income, commodities, and currencies. The strategy centers on a proprietary Quad model, a regime-based, quantitative framework that analyzes the rate-of-change in economic growth, inflation, and monetary policy trends. Portfolio allocation is based on these macro signals, identifying asset classes based on the respective market environment. Additionally, it enhances this framework with internal and external research to identify emerging themes and investment opportunities. The fund primarily invests through US-listed ETFs but may also hold individual equity and debt securities. The fund also uses an options overlay to hedge downside risk, adjust exposures, or enhance returns. Note that the portfolio is not subject to any predetermined allocation limits across specific regions.
Full HECA Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.